first
report
aptam
hbv
diagnosi
introduc
liu
et
al
select
rna
aptam
bound
specif
infect
hepatoma
cell
line
express
hepat
b
surfac
antigen
hbsag
accordingli
aptam
find
hbv
infect
cell
previou
test
purifi
antigen
use
detect
tool
find
aptam
liu
et
al
exploit
fluoresc
isothiocyan
fitc
conjug
rna
aptam
detect
hbsag
express
surfac
infect
cell
fluoresc
microscopi
replac
fitc
pharmaceut
agent
structur
design
rna
aptam
propos
group
zhijiang
xi
et
al
select
specif
singl
strand
dna
ssdna
aptam
immobil
hbsag
surfac
carboxyl
magnet
nanoparticl
mnp
selex
process
round
select
three
differ
aptam
hairpin
loop
structur
success
separ
vitro
chemiluminesc
aptasensor
base
magnet
separ
immunoassay
construct
indic
hbsag
pure
protein
form
actual
serum
sampl
result
aptasen
sampl
result
aptasensor
work
well
indic
high
specif
contribut
better
detect
hepat
b
viru
infect
detect
limit
aptasensor
ngml
five
time
lower
elisa
routin
method
examin
prove
construct
success
bound
form
hbsag
seem
investig
requir
identifi
aptam
crossreact
form
hb
ag
l
kind
interact
particl
assembl
aptam
fit
cleft
protein
surfac
particularli
activ
site
enzym
inhibit
catalyt
activ
like
tradit
antivir
small
molecul
eg
hcv
proteas
inhibitor
boceprevir
also
bind
protrud
part
protein
reason
discoveri
novel
method
reli
aptam
rapid
costeffect
diagnosi
hcv
unexpect
regard
lee
et
al
obtain
construct
biosensor
util
fluoresc
dye
rna
aptam
direct
hcv
core
antigen
via
chipbas
detect
method
wherea
chen
et
al
report
ssdna
aptam
molecular
probe
bound
viral
glycoprotein
aptam
hcv
glycoprotein
select
park
et
al
use
enzym
link
aptosorb
assay
elasa
innov
detect
assay
provid
qualit
quantit
analysi
viru
particl
test
sampl
time
addit
elasa
could
proper
method
evalu
antivir
treatment
find
might
import
earli
detect
hepat
c
patient
window
period
serum
antibodi
shown
viral
infect
yet
ordinarili
fluoresc
dyeconjug
aptam
seem
valuabl
variou
type
diagnost
assay
protect
symptomat
therapi
nucleo
ide
analogu
adefovir
lamivudin
entecavir
usual
prescrib
treatment
chronic
hepat
b
infect
although
medicin
therapeut
effect
use
restrict
sever
side
effect
develop
drugresist
strain
hbv
genom
contain
partial
relax
circular
doublestrand
dna
rcdna
mean
consist
complet
strand
strand
dna
variabl
shorter
length
hepat
progress
unusu
dna
form
coval
close
circular
dna
nucleu
activ
rna
transcript
hbv
viral
genom
translat
four
overlap
open
read
frame
includ
core
protein
c
viral
revers
dna
polymeras
p
surfac
antigen
x
protein
hbx
sever
target
protein
encod
hbv
suitabl
subject
select
aptam
interact
viral
protein
r
rnadepend
rna
polymeras
stemloop
structur
sequenc
locat
side
pregenom
rna
critic
step
replic
assembl
hbv
base
fact
feng
et
al
develop
rna
aptam
antihbv
replic
interact
viral
polymeras
high
affin
compet
bind
site
viral
genet
materi
inhibit
replic
hbv
infect
cell
line
determin
transfect
plasmid
vector
encod
rna
aptam
southern
blot
analysi
notabl
show
sign
cell
toxic
aptamertransfect
cell
zhang
et
al
found
aptam
core
protein
hbv
hbc
random
dna
pool
selex
procedur
new
aptam
demonstr
high
affin
inhibit
assembl
nucleocapsid
reduc
extracellular
dna
whose
synthesi
base
format
nucleocapsid
confirm
role
suppress
hbv
replic
aptam
suggest
new
target
molecul
facilit
strategi
target
therapi
hbvrelat
diseas
document
report
estim
kd
dissoci
constant
select
aptam
research
aptam
matrix
bind
domain
mbd
hbv
capsid
surfac
design
orabi
et
al
thirteen
round
selex
use
wild
type
wt
capsid
posit
select
mutant
capsid
counter
select
aptam
lowest
kd
select
wt
capsid
kd
valu
mutant
capsid
least
fold
higher
inhibit
potenti
test
transient
cotransfect
cell
perform
hbv
inhibit
via
inhibit
aptam
random
sequenc
aon
result
show
select
aptam
specif
mbd
entri
inhibitor
commonli
studi
therapeut
tool
prevent
viral
fusion
target
cell
penetr
viru
penetr
occur
specif
surfac
protein
cell
present
ligand
gener
proven
mani
virus
hcv
hbv
obviou
tropism
specif
cell
type
hcv
encod
two
envelop
glycoprotein
releas
host
signal
peptidas
polyprotein
precursor
hcv
infect
glycoprotein
import
target
aptam
select
glycoprotein
coreceptor
human
display
hepatocyt
b
lymphocyt
chen
et
al
obtain
dna
aptam
defin
competit
block
hcv
serotyp
effici
verifi
well
differenti
hepatocyt
deriv
carcinoma
cell
line
reduct
hcv
rna
level
protein
concentr
treatment
demonstr
qrtpcr
analysi
western
blot
assay
respect
hcv
nonstructur
protein
rnadepend
rna
polymeras
desir
target
aptam
therapeut
import
viru
replic
biroccio
et
al
construct
rna
aptam
assign
specifi
stemloop
structur
uniqu
sequenc
uauggaccaguggc
identifi
import
element
gtp
bind
site
respons
function
vitro
analysi
polymeras
activ
posit
illustr
correl
aptam
inhibit
polymeras
activ
concentrationdepend
manner
bellecav
et
al
select
dna
aptam
enzym
suppress
activ
competit
polymerasebind
site
viral
rna
templat
observ
significantli
prove
viral
copi
number
reduct
cell
line
differenti
hepatocyt
deriv
carcinoma
cell
line
infect
hcv
strain
qrtpcr
posit
correl
obtain
aptam
rna
level
viru
declin
treatment
concentr
nm
respect
compar
nonaptam
treat
cell
hcv
rna
copi
aptam
molecul
observ
intracellularli
use
confoc
microscopi
despit
absenc
transfect
agent
among
enzym
indirectli
play
role
viru
replic
nonstructur
protein
show
helicas
proteas
activ
relat
c
ntermin
domain
enzym
respect
replic
flavivirida
famili
includ
hcv
domain
essenti
proteas
domain
chang
viral
protein
necessari
life
cycl
helicas
unwind
dna
rna
duplex
unpackag
genet
materi
replic
polymeras
helicas
domain
hcv
bind
preferenti
poli
u
sequenc
situat
untransl
region
viral
genom
utr
normal
condit
umehara
et
al
creat
bival
aptam
sequenc
coupl
poli
u
linker
studi
determin
optimum
length
linker
ie
nucleotid
consequ
aptam
show
highest
synchron
reduct
helicas
proteas
activ
result
confirm
use
vitro
enzymat
assay
anoth
studi
fukuda
et
al
introduc
rna
aptam
power
competitor
sequenc
poli
u
character
vitro
enzymat
vivo
test
select
aptam
significantli
inhibit
activ
proteas
helicas
domain
dosedepend
manner
suppos
aptam
compet
hcv
utr
region
genom
bind
site
helicas
domain
nonstructur
protein
zincbind
prolinerich
hydrophil
phosphoprotein
play
critic
role
rna
replic
hcv
assembl
yu
et
al
develop
aptam
demonstr
onefold
decreas
viral
rna
level
aptam
treatment
cell
compar
control
estim
realtim
pcr
result
focu
form
assay
naiv
cell
indic
coupl
aptam
could
block
product
new
infecti
virion
seem
interferon
respons
viral
infect
remain
inact
viewpointspecif
effici
transcript
interferon
gene
evalu
qrtpcr
gao
et
al
accord
result
safeti
approach
establish
aptam
protein
nonstructur
protein
hcv
power
influenc
viral
replic
opportun
aptam
recogn
viral
protein
also
abl
detect
nucleic
acid
design
aptam
specifi
region
hcv
genom
interact
viral
life
cycl
involv
protein
appear
impress
therapeut
tool
intern
ribosom
entri
site
ire
sequenc
associ
viral
translat
wellconserv
among
hcv
isol
potenti
attract
target
antihcv
drug
ire
consist
four
domain
iiv
present
untransl
region
utr
hcv
genom
allow
cap
endindepend
mrna
translat
host
cell
intern
initi
translat
begin
bind
ire
small
ribosom
subunit
host
cell
eukaryot
translat
initi
factor
konno
et
al
render
rna
aptam
target
domain
ire
end
genom
antisens
strand
show
approxim
replic
suppress
via
vitro
analysi
two
consensu
sequenc
complet
bound
loop
domain
perform
attach
prevent
kikuchi
et
al
appli
rna
aptam
contain
loop
structur
includ
consensu
sequenc
complementari
loop
ire
domain
ii
reduct
luciferas
activ
establish
vitro
translat
test
iresluciferas
mrna
due
exposur
aptam
anoth
studi
team
research
isol
aptam
capabl
bind
iiid
domain
ire
aptam
posit
oper
viral
vitro
iresdepend
translat
blockag
target
second
domain
ire
bout
deplet
luciferas
activ
compar
control
level
detect
potenc
select
aptam
shown
transfect
hela
cell
pmol
aptam
demonstr
inhibit
luciferas
activ
especi
attent
paid
synchron
inhibit
ire
domain
ii
iiiiv
particularli
iiid
iiie
region
essenti
element
viral
translat
consequ
conjug
form
two
aptam
name
produc
prove
time
decreas
bind
affin
target
sequenc
two
parent
aptam
also
valu
show
decreas
translat
activ
lower
compon
alon
addit
romerolopez
et
al
gener
molecul
engin
aptam
compos
activ
hammer
head
ribozym
properti
typic
aptam
construct
bound
essenti
iiid
domain
ire
cleav
hcv
genom
side
inhibit
viral
translat
replic
simultan
prove
highli
potent
inhibitori
molecul
cell
contain
subgenom
rna
replicon
also
effici
inhibit
hcv
rna
synthesi
subgenom
replicon
system
qrtpcr
assay
mutat
analysi
expos
combin
aptam
variou
target
recognit
site
improv
inhibit
activ
increas
domain
bind
compet
one
main
challeng
aptam
commerci
serum
endo
exonucleas
protect
nowaday
base
nucleas
sensit
unmodifi
nucleotid
variou
chemic
modif
use
nucleotid
sugar
internucleotid
phosphodiest
linkag
modif
decreas
obvious
aptam
degrad
rate
occur
vivo
nucleas
furthermor
natur
form
nucleic
acid
replac
synthet
nucleic
acid
like
xeno
nucleic
acid
xna
unnatur
polym
mimic
dna
rna
function
demonstr
signific
enhanc
nucleas
resist
display
longer
halfliv
vivo
although
rapid
clearanc
aptam
approach
would
help
vivo
diagnost
imag
influenc
destruct
biomed
applic
renal
filtrat
threshold
thought
kd
usual
antibodi
due
larg
size
kd
special
recycl
system
circul
bloodstream
extend
halflif
clearanc
nonmodifi
aptam
happen
quickli
blood
halflif
minut
hour
howev
trick
aptam
conjug
via
high
molecular
weight
polym
like
polyethylen
glycol
peg
significantli
enhanc
halflif
physiolog
condit
also
improv
stabil
reduc
aptam
toxic
accumul
nontarget
organ
aptam
therapeut
agent
reveal
toxic
effect
ontarget
offtarget
situat
although
clinic
trial
limit
number
aptam
conduct
studi
gener
indic
moder
low
toxic
effect
aptam
investig
repres
oligonucleotid
conjug
partner
peg
highmolecular
weight
compound
may
stimul
product
antibodi
neutral
aptam
bloodstream
reduc
toxic
therapeut
potenti
applic
aptam
may
limit
intellectu
properti
right
aptam
select
technolog
wide
support
singl
intellectu
properti
portfolio
therefor
invest
area
depend
collabor
research
compani
contrast
antibodi
technolog
current
appli
broadli
lack
patent
protect
expir
intellectu
properti
right
although
protect
right
selex
method
expir
near
futur
outlin
review
recent
advanc
aptam
technolog
specif
recogn
virus
disclos
signific
potenti
rang
diagnost
therapeut
applic
molecul
convinc
substitut
antibodi
provid
effect
tool
viral
infect
manag
design
diagnost
platform
base
aptam
technolog
promis
approach
viral
infect
aptam
special
featur
detect
earli
late
viral
marker
abil
discrimin
infect
cell
normal
activ
inact
viru
look
extrem
hope
despit
obstacl
vivo
studi
sever
aptam
undergo
clinic
trial
therapeut
aptam
effect
design
appli
viral
hepat
variou
mechan
includ
blockag
virion
penetr
inhibit
viral
replic
deliveri
antivir
agent
activ
immun
system
accordingli
aptam
oper
divers
commerci
applic
combat
viral
hepat
appli
seri
modif
pharmacokinet
properti
